Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer
- 1 February 1978
- Vol. 41 (2) , 387-391
- https://doi.org/10.1002/1097-0142(197802)41:2<387::aid-cncr2820410201>3.0.co;2-x
Abstract
Ten of 23 patients with advanced measurable adenocarcinoma of the pancreas achieved an objective response after treatment with a regimen consisting of streptozotocin, mitomycin-C and 5-fluorouracil (SMF). The median duration of response is in excess of 7 months, and responding patients have lived significantly longer than patients with progressive disease (7.5+ months vs. 3 months). The SMF regimen was adequately tolerated. Principal toxicities included myelosuppression, which was generally mild, nausea and vomiting. There was reversible nephrotoxicity in the form of proteinuria in 30% of patients and persistent azotemia in 9% of patients.This publication has 11 references indexed in Scilit:
- Current Diagnosis and Management of Pancreatic CarcinomaJNCI Journal of the National Cancer Institute, 1976
- 5-FLUOROURACIL (5-FU), METHYL-CCNU, AND VINCRISTINE IN TREATMENT OF ADVANCED COLORECTAL CANCER - PHASE-2 STUDY UTILIZING WEEKLY 5-FU1976
- The integration of chemotherapy into a combined modality approach for cancer treatmentCancer Treatment Reviews, 1975
- Streptozotocin therapy in 22 cancer patientsCancer, 1975
- Clinical antitumor activity and toxicity of streptozotocin (NSC-85998)Cancer, 1974
- Chemotherapy in Pancreatic CarcinomaAnnals of Surgery, 1974
- A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancerCancer, 1974
- Renal toxicity in man treated with mitomycin CCancer, 1971
- COMBINED 5-FLUOROURACIL AND SUPERVOLTAGE RADIATION THERAPY OF LOCALLY UNRESECTABLE GASTROINTESTINAL CANCERThe Lancet, 1969
- Mitomycin-C in the therapy of far-advanced malignant tumorsCancer, 1966